LPL Financial LLC Has $433,000 Stock Holdings in Bioventus Inc. (NYSE:BVS)

LPL Financial LLC reduced its stake in shares of Bioventus Inc. (NYSE:BVS) by 3.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 41,213 shares of the company’s stock after selling 1,341 shares during the period. LPL Financial LLC owned 0.05% of Bioventus worth $433,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Plato Investment Management Ltd acquired a new stake in shares of Bioventus during the 4th quarter valued at about $38,000. KLP Kapitalforvaltning AS acquired a new position in Bioventus during the fourth quarter worth $75,000. Quantbot Technologies LP bought a new position in Bioventus during the fourth quarter valued at about $103,000. Arizona State Retirement System acquired a new stake in shares of Bioventus in the fourth quarter worth about $109,000. Finally, HighTower Advisors LLC boosted its stake in shares of Bioventus by 11.3% during the 4th quarter. HighTower Advisors LLC now owns 13,617 shares of the company’s stock worth $143,000 after acquiring an additional 1,380 shares in the last quarter. Institutional investors and hedge funds own 62.94% of the company’s stock.

Bioventus Stock Down 1.0 %

Bioventus stock opened at $7.65 on Friday. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. Bioventus Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.38. The firm has a fifty day moving average price of $9.01 and a two-hundred day moving average price of $10.47. The firm has a market cap of $626.87 million, a price-to-earnings ratio of -12.54 and a beta of 0.92.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a research note on Monday, March 17th.

Insider Activity at Bioventus

In related news, CFO Mark Leonard Singleton sold 6,498 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $66,214.62. Following the completion of the transaction, the chief financial officer now directly owns 118,817 shares in the company, valued at $1,210,745.23. This represents a 5.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Anthony D’adamio sold 4,380 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the sale, the senior vice president now directly owns 118,178 shares of the company’s stock, valued at approximately $1,204,233.82. This trade represents a 3.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,208 shares of company stock worth $226,138 in the last 90 days. 32.90% of the stock is owned by company insiders.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.